At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here?
作者信息
Carr Rotonya McCants, Lynch John P
机构信息
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
出版信息
Gastrointest Cancer Res. 2008 Sep;2(5):253-5.
Abstract
摘要
相似文献
1
At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here?胃食管交界癌管理的十字路口——我们从这里何去何从？
Gastrointest Cancer Res. 2008 Sep;2(5):253-5.
2
Crossroads in the combined-modality management of gastroesophageal junction carcinomas.胃食管交界癌综合治疗的十字路口
Gastrointest Cancer Res. 2008 Sep;2(5):235-43.
3
A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.PD-1和PD-L1抑制剂单药治疗转移性胃癌和胃食管交界腺癌的系统评价与荟萃分析
Euroasian J Hepatogastroenterol. 2020 Jul-Dec;10(2):56-63. doi: 10.5005/jp-journals-10018-1321.
4
First endoscopic submucosal dissection of gastroesophageal junction carcinoma in a 72-year old male from Saudi Arabia.首例对一名来自沙特阿拉伯的72岁男性胃食管交界癌患者进行的内镜黏膜下剥离术。
Int J Surg Case Rep. 2019;56:89-92. doi: 10.1016/j.ijscr.2019.02.034. Epub 2019 Mar 5.
5
The histopathologic spectrum of carcinomas involving the gastroesophageal junction in the Chinese.中国人胃食管交界部癌的组织病理学谱
Int J Surg Pathol. 2007 Jan;15(1):38-52. doi: 10.1177/1066896906295998.
6
Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.伊立替康和顺铂用于晚期胃癌或胃食管交界癌的治疗
Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):19-21.
7
Management of gastroesophageal tumors.胃食管肿瘤的管理
Oncologist. 2007 Feb;12(2):175-85. doi: 10.1634/theoncologist.12-2-175.
8
Endoscopically defined gastroesophageal junction coincides with the anatomical gastroesophageal junction.内镜下定义的胃食管交界与解剖学上的胃食管交界一致。
Surg Endosc. 2009 Sep;23(9):2155-8. doi: 10.1007/s00464-008-0238-9. Epub 2008 Dec 6.
9
Directional distribution of neoplasia in Barrett's esophagus is not influenced by distance from the gastroesophageal junction.巴雷特食管的肿瘤发生部位的方向性分布不受与胃食管连接部距离的影响。
Gastrointest Endosc. 2013 Jun;77(6):877-82. doi: 10.1016/j.gie.2013.01.026. Epub 2013 Mar 23.
10
Classification, diagnosis and surgical treatment of carcinomas of the gastroesophageal junction.胃食管交界部癌的分类、诊断及外科治疗
Hepatogastroenterology. 2001 Sep-Oct;48(41):1231-7.
引用本文的文献
1
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.胃食管腺癌强化新辅助化疗（FLOT）后的手术结果和围手术期并发症：强化新辅助治疗的影响。
J Gastrointest Surg. 2021 Jan;25(1):58-66. doi: 10.1007/s11605-019-04511-7. Epub 2020 Feb 10.
2
Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.新辅助治疗与辅助治疗对Siewert II型胃食管交界癌的疗效对比：基于监测、流行病学及最终结果（SEER）数据库的数据分析
J Gastrointest Oncol. 2016 Jun;7(3):403-10. doi: 10.21037/jgo.2015.10.06.
3
Proximal gastrectomy with jejunal interposition and TGRY anastomosis for proximal gastric cancer.近端胃癌的近端胃切除术加空肠间置及TGRY吻合术
World J Gastroenterol. 2014 Jul 7;20(25):8268-73. doi: 10.3748/wjg.v20.i25.8268.
本文引用的文献
1
Crossroads in the combined-modality management of gastroesophageal junction carcinomas.胃食管交界癌综合治疗的十字路口
Gastrointest Cancer Res. 2008 Sep;2(5):235-43.
2
Systemic and targeted therapy for advanced colon cancer.晚期结肠癌的全身治疗和靶向治疗
Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):135-49. doi: 10.1586/17474124.2.1.135.
3
Multidisciplinary management of gastric and gastroesophageal cancers.胃癌和胃食管癌的多学科管理
World J Gastroenterol. 2008 Jun 28;14(24):3773-80. doi: 10.3748/wjg.14.3773.
4
Epidermal growth factor receptor-directed therapy in esophageal cancer.表皮生长因子受体导向疗法在食管癌中的应用
Oncology. 2007;73(5-6):281-9. doi: 10.1159/000132393. Epub 2008 May 14.
5
A new weapon for attacking tumor blood vessels.一种攻击肿瘤血管的新武器。
N Engl J Med. 2008 May 8;358(19):2066-7. doi: 10.1056/NEJMcibr0800272.
6
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).西妥昔单抗联合FOLFIRI治疗未经治疗的晚期胃或胃食管交界腺癌患者的II期研究（FOLCETUX研究）
Ann Oncol. 2007 Mar;18(3):510-7. doi: 10.1093/annonc/mdl459. Epub 2006 Dec 12.
7
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.伊立替康、顺铂和贝伐单抗用于转移性胃或胃食管交界腺癌患者的多中心II期研究。
J Clin Oncol. 2006 Nov 20;24(33):5201-6. doi: 10.1200/JCO.2006.08.0887.
8
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.厄洛替尼用于胃食管交界腺癌和胃腺癌的II期试验：SWOG 0127
J Clin Oncol. 2006 Oct 20;24(30):4922-7. doi: 10.1200/JCO.2006.07.1316.
9
Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.食管或胃食管交界腺癌的预后因素
J Clin Oncol. 2006 Sep 10;24(26):4347-55. doi: 10.1200/JCO.2005.04.9445.
10
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.可切除的胃食管癌围手术期化疗与单纯手术治疗的比较
N Engl J Med. 2006 Jul 6;355(1):11-20. doi: 10.1056/NEJMoa055531.
Zotero 插件